Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in Early COVID-19
NCT05040724Phase 3Unknown
- Sponsor
- Groupe Hospitalier Le Raincy-Montfermeil
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivermectin in coronavirus disease 2019 (COVID-19), sponsored by Groupe Hospitalier Le Raincy-Montfermeil. Status: unknown.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05040724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040724.